Global High Flow Nasal Cannula Market Size Expected to Reach at a CAGR of 5.4% By 2034

According to the ongoing market research report presented by the CMI Team, the Global High Flow Nasal Cannula Market is poised to register a CAGR of 5.4% between the years 2025 and 2034. In 2025, the market is anticipated to touch a valuation figure of USD 3.7 billion. By the year 2034, the valuation figure is expected to reach USD 5.9 billion.

High Flow Nasal Cannula Market Overview
A medical device referred to as a High Flow nasal cannula is utilized in order to facilitate High Flow therapy, otherwise known as heated humidified High Flow therapy. Patients suffering from respiratory conditions may be treated with a constant flow of medicinal gas via the cannula, which forms part of a respiratory support system.

The most important role played by the High Flow nasal cannula is that it allows 100% oxygen and 60 liters of medical gas to be delivered per minute. The medical gas delivery system used traditionally is the nasal cannula, delivering 1-6 liters of medical gas per minute, but this has now been supplemented in part by the High Flow nasal cannula.

The medical needs of patients suffering from severe or life-threatening respiratory diseases can be met since the device accommodates high flow. Patients suffering from respiratory obstruction or failure caused by diseases such as bronchiolitis, acute exacerbations of chronic obstructive pulmonary disease (COPD), congestive heart failure, asthma, pneumonia, and a few more are typically treated with it. Because of the increasing number of patients globally, the High Flow nasal cannula industry is growing rapidly.

As per the study by JAMA Network, it is estimated that the number of COPD cases globally among those aged 25 years and older will increase by 23% from 2020 to 2050, approaching 600 million patients with COPD globally by 2050.

High Flow Nasal Cannula Market Growth Factors
Growing prevalence of smoking drives market growth

One of the causes of the market for high-flow nasal cannulas (HFNCs) growing exponentially is the increasing prevalence of smoking. Smoking is one of the primary risk factors for conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Similar to how smoking increases the prevalence of these respiratory conditions, the application of effective respiratory assistance devices such as HFNC systems is strictly necessary.

The Global Action to End Smoking study estimates that 253.0 million Indians aged 15 and older will consume tobacco products in 2022 (200.2 million men and 53.5 million women). For the number of tobacco consumers, this is second in the world and first in the WHO South-East Asia Region.

Greater cooperation is likely to florish the industry growth

The increasing partnership is likely to provide an attractive chance for market growth in the forecast period. For example, in March 2023, The Desert Oasis Healthcare (DOHC) network in California has implemented a respiratory patient monitoring program based on data from Teva's Digihaler System, as per a statement issued by Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd.

The program was developed together with Rimidi, a leading clinical management platform that is dedicated to enhancing patient experiences, reducing clinical workloads, and ensuring quality measures. The first and sole intelligent inhaler device that is capable of providing objective information in order to better assist patients and their clinicians to manage asthma is Teva's Digihaler.

Challenge in High Flow Nasal Cannula Market
High equipment cost and resulting treatment

A High Flow nasal cannula is costly. A normal High Flow nasal cannula, for instance, usually starts from USD 2000 and can go higher based on its attributes and other factors. Additionally, as per a National Institutes of Health (NIH) study, the United States average cost of utilizing a High Flow nasal cannula per patient was approximately USD 368.

High Flow Nasal Cannula Market Segmentation Analysis
By Product Type:

The single heated tube segment shall lead the market. To ensure that the oxygen being administered is both heat-warmed and humidified, single heated tubes are vital to HFNC systems. By preventing dryness of the airway and maintaining mucosal integrity, this process significantly enhances patient comfort and enhances therapeutic outcomes.

Apart from that, the nasal cannula segment has been expanding rapidly. The demand is fueled by technological innovation, rising incidence of respiratory disorders, and widening application across different health care settings. 

By Application:

The acute respiratory failure segment will lead the market. As a non-invasive alternative to conventional oxygen therapy and non-invasive ventilation, the High Flow nasal cannula is employed as a first-line support method for ARF and post-extubation. Therefore, fueling the market growth.

Conversely, the chronic obstructive pulmonary disease segment will develop with the quickest growth rate during the forecast period as a result of the rising incidences of COPD. Additionally, the growing advancements in the devices florish the market growth.